Conference
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.
Authors
Antonia SJ; Gettinger SN; Chow LQM; Juergens RA; Borghaei H; Shen Y; Harbison C; Chen AC; Ready N; Rizvi NA
Volume
32
Pagination
pp. 8023-8023
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2014
DOI
10.1200/jco.2014.32.15_suppl.8023
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X